Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Abatacept (Synonyms: CTLA4lg, BMS-188667)

Catalog No. T10218 Copy Product Info
Purity: 95%
🥰Excellent
Abatacept is a soluble recombinant fusion protein consisting of the extracellular domain of human CTLA-4 and the Fc portion of human IgG1. It binds with high affinity to CD80 and CD86 on antigen-presenting cells, specifically blocking the CD28-mediated costimulatory signal required for T-cell activation. Abatacept is widely used to investigate rheumatoid arthritis, autoimmune responses, and immune dysregulation caused by LRBA deficiency.

Abatacept

Copy Product Info
🥰Excellent
Catalog No. T10218
Synonyms CTLA4lg, BMS-188667

Abatacept is a soluble recombinant fusion protein consisting of the extracellular domain of human CTLA-4 and the Fc portion of human IgG1. It binds with high affinity to CD80 and CD86 on antigen-presenting cells, specifically blocking the CD28-mediated costimulatory signal required for T-cell activation. Abatacept is widely used to investigate rheumatoid arthritis, autoimmune responses, and immune dysregulation caused by LRBA deficiency.

Abatacept
Cas No. 332348-12-6
Pack SizePriceUSA StockGlobal StockQuantity
5 mg$813InquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:95%
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Abatacept is a soluble recombinant fusion protein consisting of the extracellular domain of human CTLA-4 and the Fc portion of human IgG1. It binds with high affinity to CD80 and CD86 on antigen-presenting cells, specifically blocking the CD28-mediated costimulatory signal required for T-cell activation. Abatacept is widely used to investigate rheumatoid arthritis, autoimmune responses, and immune dysregulation caused by LRBA deficiency.
In vitro
In co-culture assays of primary CD4+ T cells and APCs, Abatacept (100 ug/mL) blocked the CD80/86:CD28 costimulatory axis and inhibited T-cell proliferation [3]. In ex vivo analysis of cells from patients with LRBA deficiency, Abatacept modulated CTLA-4 expression levels and restored regulatory T cell function [1].
In vivo
In a rat model of collagen-induced arthritis, subcutaneous administration of Abatacept (0.1, 1, 10 mg/kg) led to dose-dependent reduction in paw edema [2]. In mouse T-cell priming models, systemic administration of Abatacept (0.5 mg/mouse) inhibited antigen-specific T-cell activation and expansion [3].
Animal Research
Animal Model: Male Lewis rats (6-9 weeks old) with weights of 150-175 g. Dosage: 10 mg/kg (i.v.), 20 mg/kg (s.c. single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29. Administration: i.v. or s.c. [2]
SynonymsCTLA4lg, BMS-188667
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Chemical Properties
Cas No.332348-12-6
Relative Density.no data available
Storage & Solubility Information
Storagestore at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Abatacept | purchase Abatacept | Abatacept cost | order Abatacept | Abatacept chemical structure | Abatacept in vivo | Abatacept in vitro